- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
XORTX Therapeutics, a company that develops therapies to inhibit the production of uric acid, has applied for listing on the Nasdaq.
|Latest market close||$0.59|
|52-week range||$0.57 - $2.48|
|50-day moving average||$0.82|
|200-day moving average||$1.21|
|Wall St. target price||$9.03|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.33|
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2023-01-27)||-3.40%|
|1 month (2023-01-04)||-31.91%|
|3 months (2022-11-04)||-25.96%|
|6 months (2022-08-04)||-58.23%|
|1 year (2022-02-04)||-61.98%|
|2 years (2021-02-04)||157.87%|
|3 years (2020-01-31)||N/A|
|5 years (2018-01-31)||N/A|
Valuing XORTX Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XORTX Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
XORTX Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, XORTX Therapeutics shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, XORTX Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
|Gross profit TTM||$0|
|Return on assets TTM||-55%|
|Return on equity TTM||78.15%|
|Market capitalisation||$8.5 million|
TTM: trailing 12 months
We're not expecting XORTX Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
XORTX Therapeutics's shares were split on a 50:587 basis on 23 September 2021. So if you had owned 587 shares the day before before the split, the next day you'd have owned 50 shares. This wouldn't directly have changed the overall worth of your XORTX Therapeutics shares – just the quantity. However, indirectly, the new 1074% higher share price could have impacted the market appetite for XORTX Therapeutics shares which in turn could have impacted XORTX Therapeutics's share price.
Over the last 12 months, XORTX Therapeutics's shares have ranged in value from as little as $0.571 up to $2.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XORTX Therapeutics's is 0.3168. This would suggest that XORTX Therapeutics's shares are less volatile than average (for this exchange).
To put XORTX Therapeutics's beta into context you can compare it against those of similar companies.
XORTX Therapeutics Inc. , a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada. .
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.